Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
594 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003237 | Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | completed | Phase 2 | 55 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00003518 | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | completed | Phase 2 | 44 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00003592 | Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 230 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00003808 | Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00005962 | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00002922 | Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 18, 2023 | clinicaltrials |
| NCT00003266 | Methylphenidate in Treating Patients With Melanoma | completed | Phase 3 | 200 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT00003764 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 280 | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 18, 2023 | clinicaltrials |
| NCT00004223 | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT00002632 | Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT00003206 | Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT00003283 | Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT00003614 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT00003864 | Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 15, 2023 | clinicaltrials |
| NCT00041314 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT00054561 | Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 5 | Jun 15, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT03433313 | Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | completed | Phase 3 | 807 | EirGenix, Inc.INDUSTRY | 11 | Jan 20, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT03090737 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer(CheckMate 907) | completed | Phase 2 | 129 | Bristol-Myers SquibbINDUSTRY | 5 | Dec 5, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT05303298 | Evaluating Acid Reflux After Oesophageal Stenting Using Anti-reflux Stents | unknown | N/A | 72 | University of Cape TownOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT00774930 | An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome(ELECT) | completed | Phase 3 | 115 | IpsenINDUSTRY | 11 | Oct 14, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT01590017 | Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer | completed | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 27, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT01095003 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | completed | Phase 3 | 770 | Pierre Fabre MedicamentINDUSTRY | 21 | Apr 28, 2022 | clinicaltrials |
| NCT03103087 | LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 382 | Myovant Sciences GmbHINDUSTRY | 8 | Apr 20, 2022 | clinicaltrials |
| NCT03049735 | LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 388 | Myovant Sciences GmbHINDUSTRY | 6 | Apr 19, 2022 | clinicaltrials |
| NCT02472964 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.(HERiTAge) | completed | Phase 3 | 500 | Mylan Inc.INDUSTRY | 15 | Feb 14, 2022 | clinicaltrials |
| NCT00982111 | First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin(INSPIRE) | completed | Phase 3 | 633 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 11, 2022 | clinicaltrials |
| NCT00703326 | Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | completed | Phase 3 | 1,144 | Eli Lilly and CompanyINDUSTRY | 23 | Dec 6, 2021 | clinicaltrials |
| NCT02136069 | A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors(GARDENIA) | completed | Phase 3 | 397 | Hoffmann-La RocheINDUSTRY | 20 | Dec 3, 2021 | clinicaltrials |
| NCT00865969 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma(PTCL) | completed | Phase 2 | 129 | Spectrum Pharmaceuticals, IncINDUSTRY | 17 | Oct 29, 2021 | clinicaltrials |
| NCT02173171 | Registry Study for Talimogene Laherparepvec | completed | — | 185 | AmgenINDUSTRY | 15 | Sep 30, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT00553358 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study(Neo ALTTO) | completed | Phase 3 | 455 | Novartis PharmaceuticalsINDUSTRY | 24 | Sep 21, 2021 | clinicaltrials |
| NCT03329911 | A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer | completed | Phase 3 | 651 | Bio-Thera SolutionsINDUSTRY | 5 | Sep 14, 2021 | clinicaltrials |
| NCT02165215 | A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors(LAUREL) | completed | Phase 3 | 359 | Hoffmann-La RocheINDUSTRY | 15 | Aug 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials